{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in tumors.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) 3.1 vs 1.0",
          "line_ref": "L31"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination leads to a broader peptide repertoire on MHC-I, improving tumor visibility to T cells.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome 62.3% vs 37.3%",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome 40.6% vs 20.6%",
          "line_ref": "L29"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C03",
      "claim": "Patients with prior SARS-CoV-2 mRNA vaccination had improved survival under ICI treatment compared to unvaccinated patients.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value p=0.01",
          "line_ref": "L30"
        },
        {
          "quote": "Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely. Vaccination timing relative to ICI initiation varied across patients."
    },
    {
      "claim_id": "C04",
      "claim": "Type I interferon signaling is required for the observed tumor sensitization effect.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        }
      ],
      "caveat": "Perturbation results may be model-specific and require confirmation across diverse tumor types."
    },
    {
      "claim_id": "C05",
      "claim": "The combination of intratumoral mRNA vaccination with checkpoint blockade increases immune cell infiltration into tumors.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change 1.8x vs 1.0x",
          "line_ref": "L33"
        },
        {
          "quote": "Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        }
      ],
      "caveat": "Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation in human settings."
    }
  ]
}
